Acetazolamide in X-linked Retinoschisis
The effect of Acetazolamide on visual acuity, retinal thickness and macular cyst size in patients with X-linked retinoschisis
The University of Sydney
30 participants
Jun 21, 2010
Interventional
Conditions
Summary
X-linked retinoschisis is a genetic eye disorder characterised by abnormal splitting of the retina, resulting in a loss of vision. Currently there is no treatment available for X-linked retinoschisis. However, an improvement in sight has been reported following the use of topical and oral acetazolamide in people with X-linked retinoschisis. Hence, the objective of this study is to investigate whether oral acetazolamide improves the sight of people with X-linked retinoschisis.
Eligibility
Inclusion Criteria2
- Patients with X-linked retinoschisis diagnosis and stable ocular fixation with no clinically significant media opacities.
- There will be no age restrictions
Exclusion Criteria13
- Hypersensitivity to sulphonamides and sulphonamide derivatives
- Women who are pregnant
- People in existing dependent or unequal relationships
- People highly dependent on medical care
- Aboriginal and/or Torres Striait Islander People
- People who may be involved in illegal activity
- People with an intellectual or mental impairment
- People whose primary language is other than English.
- A refractive error greater than ±6 diopters (D) sphere
- Uveitis
- Optic neuropathy
- The presence of nystagmus or any other retinal diseases affecting the macula other than retinoschisis
- A recent history (<6months) of intraocular surgery, and poor optical coherent tomography (OCT) image quality.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral acetazolamide 200mg twice a day >60kg or 125mg twice <60kg. Participants allocated to the acetazolamide/placebo study arm will receive acetazolamide first, followed by placebo, and vice versa in the placebo/acetazolamide. The duration of acetazolamide will be three months. The mode of administration is oral capsule. Cross over occurs at 3 months following first dose of treatment. Measurements at are done at 0, 3 and 6months. Hence no "wash-out" period is required.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12610000476033